FDA issues CRL for Braeburn's opioid addiction candidate

Braeburn Pharmaceuticals Inc. (Princeton, N.J.) said FDA issued a complete response letter for an NDA for its monthly buprenorphine injection depot CAM2038 to treat opioid use

Read the full 264 word article

User Sign In